Table 2.
The correlation between clinicopathological features and the expression of EHD1
| EHD1 (n=85)ª | |||
|---|---|---|---|
| Variables | Low | Strong | P |
| Age | 0.364 | ||
| ≤60 | 27(31.76%) | 39(45.88%) | |
| >60 | 10(11.76%) | 9(10.59%) | |
| Gender | 0.521 | ||
| male | 19(22.35%) | 28(32.94%) | |
| female | 18(21.18%) | 20(23.53%) | |
| Smoking history | 0.546 | ||
| never | 1(1.18%) | 4(4.71%) | |
| ever | 20(23.53%) | 25(29.41%) | |
| unknown | 16(18.82%) | 19(22.35%) | |
| Adjuvant radiotherapy | 0.828 | ||
| Yes | 10(11.76%) | 14(16.47%) | |
| No | 27(31.76%) | 34(40.00%) | |
| Tumor histology | 0.462 | ||
| pure | 35(41.18%) | 43(50.59%) | |
| combined | 2(2.35%) | 5(5.88%) | |
| Tumor Size | 0.019* | ||
| ≤3 | 14(16.47%) | 25(29.41%) | |
| >3 | 24(28.24%) | 22(25.88%) | |
| Nodal | 0.290 | ||
| negative | 22(25.88%) | 23(27.06%) | |
| positive | 15(17.65%) | 25(29.41%) | |
| AJCC Stage | 0.781 | ||
| I | 17(20.00%) | 20(23.53%) | |
| II | 11(12.94%) | 13(15.29%) | |
| III | 9(10.59%) | 15(17.65%) | |
note: [0 (negative) ≤ score ≤ 1+] and [2+ ≤ score ≤ 3+] represent low negative and strong positive staining of EHD1, respectively. All the cut off points contributed to acquiring the optimum balance ratio between negative and positive. * P < 0.05. ª. Three EHD1 samples were excluded because of damage to or cytolysis of the paraffin block.